
ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess
England
Joined February 2009
- Tweets21.9K
- Following4.4K
- Followers17.1K
- Likes6.3K
ecancer presents a free live interactive webinar on the latest in #bladdercancer on 16 November 17:00 GMT/18:00 CET. Register here for expert analysis 👉ecancer.org/bladder #ESMO26 #EMUC2026 #EMUC26 @AlisonBirtle @nachoduranm @amerseburger @MRoupret
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC. Watch Dr Alex Spira discuss his study 👉ow.ly/1nIT50ZYsIY @AlexSpiraMDPhD @VCSpecialists #NSCLC #Oncology #WCLC2026
ecancer retweeted
Our newly published work in @ecancer! 🌍
Together with @assoGFAOP, we implemented a structured health-system assessment/improvement framework across pediatric oncology centers in Francophone Africa, identifying priorities & building a path to action.🎗️
ecancer.org/en/journal/artic…
ecancer retweeted
Hot off the press!
Quality indicators of pathology and laboratory medicine in cancer: a narrative synthesis of published literature - ecancer
#ecancer @ecancer
ecancer.org/en/journal/artic…
Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 ecancer.org/telepathology #BreastCancer #oncology
ecancer retweeted
🚀 Opening #IUCS26 | More than a meeting a growing global GU oncology community
One of the things that struck me most from the opening session was the clarity of the vision behind IUCS: to build a truly international, multidisciplinary community around better care for patients with GU cancers.
With the creation of IUCS CIC, that vision now has a formal non-profit structure focused on:
⚪ multidisciplinary care
⚪ translational and investigator-led research
⚪ evidence-based innovation
⚪ education and global collaboration
⚪ connecting science with everyday clinical practice
What makes this especially meaningful is the diversity of perspectives brought together across countries, specialties and healthcare systems — all around one shared goal:
better outcomes for our patients.
A great way to begin two days of science, discussion and collaboration in Guildford.
With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty.
@myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb
#GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology
🚀 Opening #IUCS26 | From a meeting to a global GU oncology community
The opening session highlighted the vision behind IUCS and the creation of IUCS CIC, a non-profit Community Interest Company dedicated to advancing multidisciplinary care, translational research and clinical education across genitourinary cancers.
⚪ Building an international and multidisciplinary GU oncology community
⚪ Accelerating evidence-based innovation
⚪ Connecting translational research with everyday clinical practice
⚪ Strengthening education, collaboration and investigator-led research
⚪ Bringing together expertise across countries and healthcare systems
⚪ Keeping the ultimate goal clear: better outcomes for our patients
Great to see the community gathered in Guildford and ready for two days of science, discussion and collaboration.
With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @nataliagandur @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty.
@myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb
#GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology
At #EHA2026, Dr Fredrick Chen discusses UK ITP Registry data showing rapid and robust platelet responses with early romiplostim in acute ITP. Watch the full interview👉bit.ly/4cHSLb2 #ITP #Haematology
At #ESMOGI26, Dr Kozo Kataoka (@HyomedGastro) discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 bit.ly/4xxdpmA
#CRC #ctDNA #MRD #PrecisionMedicine
At #ESMOGI26, @CentralParkWMD discusses GLEAM results. Zolbetuximab plus gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉bit.ly/3UyJiN6
At #ESMOGI26, @TaberneroJosep discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉bit.ly/4qxthTJ
At #ESMOGI26, Dr Michele Milella (@UniVerona) discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉bit.ly/4gPfULa
At #ESMOGI26, Dr Nilo Azad (@hopkinskimmel) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity. Watch interview👉bit.ly/3S6hM94
At #EHA2026, Prof Martin Schrappe (@UKSH_KI_HL) discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉bit.ly/3U8C56h
At #EHA2026, @MarekTrnenyDr discusses phase 2 CHEPA results showing brentuximab vedotin plus CHP and etoposide achieved a 91% ORR and 76% complete metabolic response rate in previously untreated CD30+ PTCL. Watch the interview👉bit.ly/4xlUgny #Lymphoma #Haematology
At #EHA2026, Prof Umberto Vitolo (@fprc_candiolo) discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉bit.ly/4cOoYNX #Haematology
Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 ecancer.org/telepathology #BreastCancer #oncology
At #EHA2026, Prof Umberto Vitolo (@fprc_candiolo) discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉bit.ly/4wzkKko #DLBCL #Haematology
At #EHA2026, Prof Anthony Moorman (@UniofNewcastle) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview 👉 bit.ly/3RWO6ex #ALL
At #EHA2026, @carsten_niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉bit.ly/4x2NT8x #CLL #Haematology
At #EHA2026, @chanyooncheah discusses phase 3 SOUNDTRACK F1 results showing surovatamig plus rituximab achieved response rates of 95–100% and CR rates of around 84–85% in previously untreated FL. Watch full interview👉 bit.ly/4wrfAqu
#FollicularLymphoma #Haematology









